Search Results - "Randall, L.M."

A phase II, single-dose, open-label study to investigate the safety and efficacy of OTL38 injection for intraoperative imaging of folate receptor-alpha positive ovarian cancer by Randall, L.M, Wenham, R.M, Low, P.S, Dowdy, S.C, Tanyi, J.L

Get full text

Racial disparities and patterns of ovarian cancer surgical care in California by Liu, F.W, Randall, L.M, Tewari, K.S, Bristow, R.E

“…Abstract Objective To investigate disparities in the frequency of ovarian cancer-related surgical procedures and access to high-volume surgical providers among…”
Get full text

Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer by Bristow, R.E, Randall, L.M, Liu, F, Chang, J, Ziogas, A, Anton-Culver, H

Get full text

Flavokawain B (FKB), a novel naturally occurring chalcone, exhibits robust apoptotic effects in the treatment of a uterine leiomyosarcoma cell line by Eskander, R.N, Randall, L.M, Sakai, T, Guo, Y, Hoang, B, Zi, X

Get full text

p53 Restoration in Ovarian Carcinoma Harnessing a Genetic Aberration by Minion, L.E., Tofig, B., Randall, L.M., Kaiser, P.

Get full text

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO) by Pothuri, B., Blank, S.V., Myers, T.K., Hines, J.F., Randall, L.M., O'Cearbhaill, R.E., Slomovitz, B.M., Eskander, R.N., Alvarez Secord, A., Coleman, R.L., Walker, J.L., Monk, B.J., Moore, K.N., O'Malley, D.M., Copeland, L.J., Herzog, T.J.

Get full text

883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer by Randall, L.M., O'Malley, D.M., Monk, B.J., Coleman, R.L., O'Cearbhaill, R.E., Gaillard, S., Adams, S., Cappuccini, F., Huang, M., Chon, H.S., Secord, A.A., Arora, S., Keeton, E., Gupta, D., Samnotra, V., Konstantinopoulos, P.

Get full text

Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial by Ledermann, J.A., Colombo, N., Oza, A.M., Fujiwara, K., Birrer, M.J., Randall, L.M., Poddubskaya, E.V., Scambia, G., Shparyk, Y.V., Lim, M.C., Bhoola, S.M., Sohn, J., Yonemori, K., Stewart, R.A., Zhang, X., Zohren, F., Linn, C., Monk, B.J.

Get full text

LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials by O'Malley, D.M., Oaknin, A., Monk, B.J., Leary, A., Selle, F., Alexandre, J., Randall, L.M., Rojas, C., Neffa, M., Kryzhanivska, A., Gladieff, L., Berton, D., Meniawy, T., Lugowska, I., Bondarenko, I., Moore, K.N., Ortuzar Feliu, W.I., Ancukiewicz, M., Shapiro, I., Ray-Coquard, I.L.

Get full text

GOG 8035: Nuclear BRCA1 loss may identify a poor prognostic subgroup of women with locally advanced cervical cancer treated with cisplatin-based chemoradiation: An NRG Oncology study by Longoria, T.C., Sill, M., Monk, B.J., Fruehauf, J., Liao, S.Y., Emerson, R., Kim, J.H., Mannel, R.S., Lee, Y.C., Mathews, C.A., Randall, L.M., Darcy, K.M., Birrer, M.J., Tewari, K.S.

Get full text

Initial investigation of combined single-photon emission computed tomography (SPECT) and magnetic resonance (MR) imaging of a human ovarian tumor xenograft using 123I-bevacizumab by Randall, L.M., Hamamura, M.J., Harris, D.H., Ha, S., Roeck, W., Nalcioglu, O.

Get full text